Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study

C. Paul; Christopher Em Griffiths; P.C.M. van de Kerkhof; L. Puig; Yves Dutronc; Carsten Henneges; Martín Dossenbach; Kristin Hollister; Kristian Reich

doi:10.1016/j.jaad.2018.06.039

Related publications

Article2009

Indacaterol Once-Daily Provides Sustained 24-h Bronchodilation over 52 Weeks of Treatment in COPD.

Ronald E Dahl, P Kolman, DB Jack, Roger Owen, Benjamin Krämer, Mark Higgins

Article2008

Efficacy and safety of continuous versus paused etanercept treatment in patients with moderate-to-severe psoriasis over 54 weeks: the CRYSTEL study

Jean‐Paul Ortonne, Christopher Em Griffiths, E. Daudén, Robert Strohal, Deborah Robertson, Ronald Pedersen, C. Molta, Bruce Freundlich

Article2015

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

Christopher Em Griffiths, Kristian Reich, Mark Lebwohl, Peter van de Kerkhof, C. Paul, Alan Menter, Gregory S. Cameron, J. Erickson, Lu Zhang, Roberta J. Secrest, Susan Ball, Daniel Braun, Olawale Osuntokun, Michael Heffernan, Brian J. Nickoloff, Kim Papp

Article2024

Efficacy and Safety of Iptacopan in Patients with C3 Glomerulopathy: 12-Month Results from the Phase 3 APPEAR-C3G Study

Carla Nester, Richard J. Smith, David Kavanagh, Marina Vivarelli, Giuseppe Remuzzi, Ming‐Hui Zhao, Edwin Wong, Yaqin Wang, Angelo J. Trapani, Ipsita Krishnan, Nicholas J.A. Webb, Matthias Meier, Andrew S. Bomback

Preprint2023

Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures. The multicenter, prospective, real-life FRIEND2 study.

Piero Barbanti, Gabriella Egeo, Cinzia Aurilia, Paola Torelli, Cinzia Finocchi, Florindo d’Onofrio, Luigi d'Onorio, Renata Rao, Stefano Messina, Laura Di Clemente, Angelo Ranieri, Massimo Autunno, Giuliano Sette, Bruno Colombo, Antonio Carnevale, Marco Aguggia, Miriam Tasillo, Francesco Zoroddu, Fabio Frediani, Massimo Filippi, Giulia Fiorentini,

Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study

Discussion(0)